TY - JOUR
T1 - Coproduction of KPC-18 and VIM-1 Carbapenemases by Enterobacter cloacae
T2 - Implications for Newer β-Lactam'β-Lactamase Inhibitor Combinations
AU - Thomson, Gina K.
AU - Snyder, James W.
AU - McElheny, Christi L.
AU - Thomson, Kenneth S.
AU - Doi, Yohei
N1 - Funding Information:
Y.D. has served on advisory boards for Shionogi, Meiji Seika Pharma, and Tetraphase Pharmaceuticals; consulted for Melinta Therapeutics; and received research funding from Merck and The Medicines Company for studies unrelated to this work. All other authors declare no conflicts of interest. Office of Extramural Research, National Institutes of Health (OER) provided funding to Yohei Doi under grant number R01AI104895. Office of Extramural Research, National Institutes of Health (OER) provided funding to Yohei Doi under grant number R21AI107302.
Publisher Copyright:
© 2016, American Society for Microbiology. All Rights Reserved.
PY - 2016/3
Y1 - 2016/3
N2 - Enterobacter cloacae strain G6809 with reduced susceptibility to carbapenems was identified from a patient in a long-term acute care hospital in Kentucky. G6809 belonged to sequence type (ST) 88 and carried two carbapenemase genes, blaKPC-18 and blaVIM-1. Whole-genome sequencing localized blaKPC-18 to the chromosome and blaVIM-1 to a 58-kb plasmid. The strain was highly resistant to ceftazidime-avibactam. Insidious coproduction of metallo-β-lactamase with KPC-type carbapenemase has implications for the use of next-generation β-lactam'β-lactamase inhibitor combinations.
AB - Enterobacter cloacae strain G6809 with reduced susceptibility to carbapenems was identified from a patient in a long-term acute care hospital in Kentucky. G6809 belonged to sequence type (ST) 88 and carried two carbapenemase genes, blaKPC-18 and blaVIM-1. Whole-genome sequencing localized blaKPC-18 to the chromosome and blaVIM-1 to a 58-kb plasmid. The strain was highly resistant to ceftazidime-avibactam. Insidious coproduction of metallo-β-lactamase with KPC-type carbapenemase has implications for the use of next-generation β-lactam'β-lactamase inhibitor combinations.
UR - http://www.scopus.com/inward/record.url?scp=84959570300&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959570300&partnerID=8YFLogxK
U2 - 10.1128/JCM.02739-15
DO - 10.1128/JCM.02739-15
M3 - Article
C2 - 26719440
AN - SCOPUS:84959570300
VL - 54
SP - 791
EP - 794
JO - Journal of Clinical Microbiology
JF - Journal of Clinical Microbiology
SN - 0095-1137
IS - 3
ER -